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TOXICOLOGY

Identification and Management of Cobalt Toxicity:
A Case Report of Rapidly Progressing Toxicity
after Hip Arthroplasty Revision
Neena Mohan, MD and Eric Kasprowicz, MD

INTRODUCTION
Patients undergoing total hip arthroplasty represent a
growing portion of the population. More than 330,000
hip replacements are performed annually1, and more than
2.5 million Americans are living with a hip prosthesis2.
Many hardware configurations utilize metal alloys for the
femoral head and/or acetabulum. Although their use is
decreasing due to safety concerns, cobalt-chromium
femoral heads were still used in 51% of total hip arthroplasties in 20143. There is rising concern about the
adverse effects of metal ions released from these joint
replacements. However, little published evidence is
available supporting specific interventions for the
management of cobalt toxicity.

Figure 1. Cross-sectional MRI imaging with Metal Artifact Reduction Sequence
(MARS) Protocol to diminish the signal intensity from metallic objects demonstrates
local invasion of metallic content into tissue surrounding the joint.

Given the increasing incidence and prevalence of total
hip arthroplasty in the United States, patients with total hip
replacements will become more commonplace in the
internist’s practice. With the risk of adverse effects related
to these prostheses, it is important to be familiar with the
presentation of cobalt toxicity in order to spare patients
from excessive or irreversible damage.

CASE PRESENTATION
The patient is a 61 year-old female with a past medical
history of total hip arthroplasty in 2004 with a ceramic
prosthesis who had a cobalt-chromium prosthetic revision
in May 2015. The old prosthesis was found to be shattered
during the second operation, and although attempts were
made to extract all the fragments, it was noted that the
surgeons were unable to remove all of the particulate
ceramic debris. Two months later, the patient began
noticing bilateral hearing loss and blurry vision that
progressively worsened, as well as peripheral neuropathy
in her hands and feet. She also developed hypothyroidism
and was started on levothyroxine. Due to persistent
abdominal pain, decreased appetite and weight loss, the
patient had an endoscopy which revealed severe
gastritis. At an outpatient neurology evaluation, the
patient’s whole blood cobalt level was found to be 2,128
mcg/L (reference <3 mcg/L). She was admitted to
Thomas Jefferson University Hospital for management
of progressively worsening symptoms and for hip
arthroplasty revision evaluation.
The patient’s initial serum cobalt level during hospitalization was 1254 mcg/L (reference 0.1-0.4 mcg/L) and the
whole blood cobalt level was 1997.0 mcg/L (reference
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Figure 2. Cross-sectional CT imaging of the patient’s affected hip, demonstrating
extensive local tissue inflammation extending along the affected joint.

<1.8 mcg/L). Physical examination revealed decreased
visual acuity and decreased hearing bilaterally. She had
decreased reflexes in the lower extremities bilaterally and
intact sensation. Lower extremity strength bilaterally was
limited by pain.

DIFFERENTIAL DIAGNOSIS
Given the patient’s constellation of symptoms and lack
of other significant past medical history, the differential
in this case was relatively limited. The important lesson
from this case is the need to identify symptoms of cobalt
toxicity early in patients with prior hip arthroplasty.
Clinically significant effects of cobalt poisoning rarely
appear below a whole blood level of 300 mcg/L4. Above
this level, patients may begin to develop many of the
same symptoms displayed here: neurotoxicity including
optic nerve damage, thyroid toxicity, and fatigue and
weakness5. Cases of severe cobalt toxicity have even led
to mortality from worsening dilated cardiomyopathy6.
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OUTCOME AND FOLLOW-UP
Early in the admission, CT and MRI of the hip demonstrated
a large area of metallic infiltration (Figure 1) and
inflammation (Figure 2) in the surrounding tissues.
Nephrology recommended plasmapheresis to attempt to
reduce the cobalt burden. On the initial day of plasmapheresis, the patient's whole blood cobalt level was 1891
mcg/L. The next day, the whole blood cobalt level had
fallen to 1509 mcg/L. Orthopedic surgery performed a left
hip arthroplasty revision, during which time a significant
amount of cobalt was found and removed from the joint.
After the operation, the whole blood cobalt level had
decreased to 447 mcg/L.
During the hospitalization, plasmapheresis was eventually
discontinued, as there was little literature to support its use
in cobalt toxicity and it did not significantly reduce cobalt
levels. Chelation was recommended, and patient received
one day of treatment with N-acetylcysteine (NAC) after
her operation.
Other complications which arose during the hospitalization included lactic acidosis and diabetes insipidus,
thought to be secondary to cobalt toxicity. These
complications, along with the patient’s severe gastritis,
have not previously been attributed to cobalt toxicity in the
literature. However, given the patients few medical
comorbities and onset corresponding with the elevation in
cobalt levels, it is likely that they may represent previously
undescribed complications of cobalt toxicity. The patient’s
vision loss was attributed by ophthalmology to optic
neuropathy and possible retinal toxicity from cobalt. After
20 days of hospitalization, the patient’s decreased visual
acuity and hearing were only mildly improved, her
peripheral neuropathy persisted, and her thyroid stimulating
hormone level was 29.47 uIU/mL (nl 0.3-5.0 uIU/mL). The
whole blood cobalt level after a second left hip irrigation
prior to discharge was 247 mcg/L.

DISCUSSION AND MANAGEMENT
A notable element of this case is the accelerated
development of toxicity after recent revision. This has been
found most commonly after shattering of a ceramic joint
(5,6). Revisions are complicated by an inability to completely
remove all the shattered ceramic components, and it is
believed that retained particles create shearing in the newly
placed joint that accelerates the release of metal ions.
There is no consensus regarding management of patients
with systemic symptoms of cobalt toxicity. Clinical
response to different treatments is not consistently
documented in current literature. The main objective is to
eliminate exposure to cobalt and treat systemic symptoms
supportively, such as with thyroid hormone replacement
therapy for hypothyroidism, and beta blockers and diuretics
for cardiomyopathy7.
In a study evaluating the effects of administration of
glutathione, NAC, 2,3-dimercaptosuccinic acid (DMSA),
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ethylendiamine-tetraacetic acid (EDTA), and diethylentriamepentaacetic acid (DTPA) for five days in rats, the urinary
excretion of cobalt was significantly increased by
glutathione, NAC and DTPA. However, the concentration
of cobalt in the various tissues of the body was only
decreased by NAC (liver and spleen) and glutathione
(spleen) 8. EDTA has been the predominant chelator
administered to humans. In a 2011 study, it provided
short-term lowering of blood cobalt measurements;
however, cobalt concentrations rebounded within days.
This trend occurs because while EDTA binds and removes
part of the soluble ions present in plasma, there continues
to be further release of ions from the active surface9.
There is little human evidence available to support
recommendations for cobalt chelation. The National
Council on Radiation Protection and Measurements and
the Radiation Emergency Assistance Center/Training Site
recommend DTPA for cobalt radionuclide chelation, while
also stating that DMSA, EDTA, and NAC can be considered.
For non-radiologic exposure, other sources suggest that
both NAC and EDTA can be considered, without a definitive
recommendation10.
There is no conclusive evidence regarding the utility of
plasmapheresis in cobalt toxicity. In one case of a 22 year
old male with oral dichromate intoxication, five treatment
sessions of plasmapheresis significantly lowered his serum
and urinary chromium concentrations11. This case report
contributed to the consideration of plasmapheresis as part
of the management plan in our patient.
Revision surgery appears to be effective in removal of the
systemic cobalt burden. A 2015 study evaluated blood
metal ion levels in patients who underwent revision
surgery for adverse effects due to cobalt and chromium
debris. There was a decrease in blood cobalt in all patients
who had unilateral surgery at one year of follow up. In
some patients with bilateral metal-on-metal hip
prostheses, cobalt levels remained elevated, but this
could be attributed to the confounding effect of the
contralateral metal-on-metal implant12.

KEY POINTS
• Patients with elevated cobalt blood levels after metalcontaining total hip arthroplasties are at risk for
significant clinical sequelae, including vision and
hearing loss, peripheral neuropathy, hypothyroidism,
and cardiomyopathy.
• Severe gastritis, lactic acidosis and diabetes insipidus
may also be seen in cobalt toxicity.
• There is currently no consensus regarding the appropriate
management of cobalt toxicity. These patients should
be considered for prosthetic revision to attempt to
decrease cobalt systemic burden. Chelation with NAC
and EDTA may be used as adjunctive therapy. Additional
research is warranted to evaluate the optimal timing of
revision surgeries and chelation therapy.
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